Table S6. Associations between combined SNPs identified in this study and all previously published in the present study populations and survival of NSCLC in the PLCO Trial.
| Number of risk genotypes1 | Number2 | OS3 | DSS3 | |||||
|---|---|---|---|---|---|---|---|---|
| Death, n (%) | HR (95% CI) | P | Death, n (%) | HR (95% CI) | P | |||
| 3 | 10 | 7 (70.00) | 1.00 | 5 (50.00) | 1.00 | |||
| 4 | 31 | 20 (64.52) | 0.63 (0.26–1.54) | 0.312 | 15 (48.39) | 0.69 (0.24–1.94) | 0.479 | |
| 5 | 75 | 36 (48.00) | 1.13 (0.49–2.56) | 0.778 | 34 (45.33) | 1.45 (0.56–3.74) | 0.444 | |
| 6 | 157 | 100 (63.69) | 1.75 (0.80–3.82) | 0.162 | 87 (55.41) | 2.01 (0.81–5.01) | 0.135 | |
| 7 | 215 | 119 (55.35) | 1.78 (0.82–3.88) | 0.146 | 111 (51.63) | 2.26 (0.91–5.62) | 0.078 | |
| 8 | 251 | 176 (70.12) | 2.69 (1.24–5.81) | 0.012 | 159 (63.35) | 3.27 (1.33–8.07) | 0.010 | |
| 9 | 197 | 153 (77.66) | 2.97 (1.37–6.44) | 0.006 | 136 (69.04) | 3.43 (1.39–8.49) | 0.008 | |
| 10 | 123 | 96 (78.05) | 3.15 (1.43–6.93) | 0.004 | 85 (69.11) | 3.66 (1.46–9.17) | 0.006 | |
| 11 | 57 | 44 (77.19) | 3.99 (1.76–9.04) | 0.001 | 40 (70.18) | 4.90 (1.90–12.63) | 0.001 | |
| 12 | 8 | 8 (100.00) | 5.07 (1.77–14.52) | 0.003 | 7 (87.50) | 6.01 (1.84–19.58) | 0.003 | |
| 13 | 1 | 0 (0.00) | – | – | 0 (0.00) | – | – | |
| Trend | <0.001 | <0.001 | ||||||
| 3–7 | 488 | 282 (57.79) | 1.00 | – | 252 (51.64) | 1.00 | – | |
| 8–13 | 637 | 477 (74.88) | 1.99 (1.71–2.31) | <0.001 | 427 (67.03) | 1.94 (1.66–2.28) | <0.001 | |
1, risk genotypes were ABCG1 rs225390 AA, ADAM12 rs10794069 AG+GG, DTX1 rs1732793 GA + AA, E2F3 rs3806116 GT+TT, IRAK2 rs779901 CC, VWF rs73049469 CA + AA, ITGB2 rs3788142 GA + AA, RUNX3 rs7553295 GG, AMD1 rs1279590 GG, MSRA rs73534533 CC, TNFRSF1B rs677844 TT, IKBKAP rs4978754 CC, PLCG2 rs9673682 TT and PLPP1 rs115613985 TA + AA; 2, 60 missing date were excluded, no patients with 0, 1, 2 or 14 risk genotypes; 3, adjusted for age, sex, smoking status, histology, tumor stage, chemotherapy, radiotherapy, surgery and principal components. SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; OS, overall survival; DSS, disease-specific survival; HR, hazards ratio; CI, confidence interval.